Jun Shi
Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical College Principal Investigator · Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical School · Institute of Hematology & Blood Diseases Hospital, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jun Shi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:45 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07816341 · F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Autoimmune Hemolytic Anemia · principal investigator
- Ph1/Ph2NCT07714512 · Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Aplastic Anemia · principal investigator
- Ph1NCT07091370 · Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of TherapyJuventas Cell Therapy Ltd. · not yet recruiting · AIHA - Cold Autoimmune Hemolytic Anemia · principal investigator
- Ph1NCT07075484 · A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaChina Immunotech (Beijing) Biotechnology Co., Ltd. · completed · Autoimmune Hemolytic Anemia · study chair
- Ph2NCT07010237 · Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic AnemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment · principal investigator
- Ph1/Ph2NCT06792019 · Study of CM313(SC) Injection in Subjects With Platelet Transfusion RefractorinessKeymed Biosciences Co.Ltd · recruiting · Platelet Transfusion Refractoriness · principal investigator
- Ph1/Ph2NCT06791824 · Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic AnemiaKeymed Biosciences Co.Ltd · not yet recruiting · Aplastic Anemia · principal investigator
- Ph2NCT06613880 · Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic AnemiaInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · Aplastic Anemia, TPO Receptor Agonists · principal investigator
- Ph2NCT06503276 · The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · recruiting · Extranodal Marginal Zone B-cell Lymphoma · principal investigator
- N/ANCT06287086 · Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell DiseaseBioray Laboratories · unknown · Sickle Cell Disease · study chair
- Ph2NCT06224257 · Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Relapsed/Refractory Large Granular T Lymphocytic Leukemia · principal investigator
- N/ANCT06041620 · Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem CellsInstitute of Hematology & Blood Diseases Hospital, China · terminated · Thalassemia, Beta, Thalassemia Major · principal investigator
- Ph2NCT04423367 · Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line TreatmentInstitute of Hematology & Blood Diseases Hospital, China · completed · Acquired Pure Red Cell Aplasia · principal investigator
- N/ANCT04390971 · Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-ThalassaemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Transfusion Dependent Beta-Thalassaemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 65 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:45 UTC. The ranking covers the 200 most relevant of 747 PubMed records, and a shared surname and initials can bring in a namesake. All 747 on PubMed
- 662 citationsRCR 52.6
- Effect of Salt Substitution on Cardiovascular Events and Death.N Engl J Med · 2021602 citationsRCR 39.9
- 593 citationsRCR 30.9
- 561 citationsRCR 18.1
- 473 citationsRCR 29.1
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.Cancer Cell · 2022462 citationsRCR 28.6
- 408 citationsRCR 19.3
- 309 citationsRCR 23.8
- 308 citationsRCR 35.6
- 306 citationsRCR 18.8